Personalis, Inc.
PSNLNext catalyst
Elacestrant
ER+ Breast Cancer
Get an email about PSNL's next catalysts
Track Personalis (PSNL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 2 past
Elacestrant Phase 2 Est. Readout
Estimated primary completion for Elacestrant trial (NCT06923527) in ER+ Breast Cancer. Topline data typically follows completion by weeks to months.
SourceAZD2936 Phase 2 Est. Readout (MERIDIAN)
Estimated primary completion for AZD2936 trial (NCT05414032) in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Elacestrant
ER+ Breast Cancer
AZD2936
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Elacestrant | Phase 2 | ER+ Breast Cancer | - | - |
AZD2936 | Phase 2 | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | - | - |
Frequently asked questions
What is in Personalis, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Personalis, Inc.'s (PSNL) pipeline across Phase 2. Its lead program is AZD2936 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Personalis, Inc.'s next FDA catalyst?→
Personalis, Inc.'s (PSNL) next tracked catalyst is a Phase 2 readout expected September 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PSNL biotech catalysts?→
Add PSNL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Personalis, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.